We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Grants New RMAT Designation Humacyte Vascular Tissue Therapy
FDA Grants New RMAT Designation Humacyte Vascular Tissue Therapy
The FDA granted expedited review to Humacyte’s tissue therapy under the new Regenerative Medicine Advanced Therapy pathway — one of the first products to receive the designation established by the 21st Century Cures Act.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor